anastrozole / Generic mfg. - LARVOL DELTA

Clinical investigators' (CIs) practice patterns for patients with hormone receptor-positive metastatic breast cancer (HR+ mBC) harboring PI3K/AKT/PTEN pathway abnormalities (PAPm). (ASCO 2025) - "The recent availability of capi and inavo has significantly affected current practice patterns, with the majority of CIs rapidly incorporating these therapies into their treatment algorithms for specific patient types. Future work is needed to explore how other factors (eg, age, comorbidities, HER2-low status) and rapidly emerging clinical trial findings (eg, EMBER-3) affect decision-making. A = anastrozole; IPF = inavolisib + palbociclib + fulvestrant; F = fulvestrant; AI = aromatase inhibitor; C = capivasertib; Alp = alpelisib; E = elacestrant"

Clinical • Metastases • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PIK3CA • PTEN

A Rare Case of Metastasis of Renal Cell Carcinoma to Thyroid Gland presenting as Neck Mass, Four Years After Nephrectomy. (ENDO 2025) - "Her cancer history also included right breast ductal carcinoma in situ (DCIS), diagnosed in 2011, and left breast invasive ductal carcinoma (IDC) in 2019, for which she underwent lumpectomy and currently on anastrozole.The patient had been disease-free post-surgery with routine follow-up, including CT scans and renal ultrasounds, whit no signs of recurrence...These findings further supported the diagnosis of thyroid metastasis from RCC.This case underscores the importance of ongoing surveillance in RCC survivors, even many years after initial treatment, as metastasis can occur long after the primary disease is considered "disease-free." Thyroid metastasis from RCC, while rare, should be considered in the differential diagnosis of thyroid nodules in patients with a history of RCC, mainly when unusual presentation patterns occur. This case contributes to understanding RCC metastasis to the thyroid, emphasizing the need for vigilance in follow-up care and..."

Clinical • Breast Cancer • Endocrine Disorders • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • BRAF • CA9 • MME • NKX2-1 • PAX8

A Case of Anastrozole Induced Hyperandrogenism (ENDO 2025) - "Patient was switched from anastrozole to exemestane by her oncologist and was started on spironolactone for persisting hirsutism and scalp hair thinning. Anastrozole as a cause of hirsutism or hyperandrogenism has not been commonly described and may be considered after exclusion of more serious causes."

Clinical • Acne Vulgaris • Alopecia • Breast Cancer • Diabetes • Endocrine Disorders • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Leydig Cell Tumor: A Rare Cause of Hyperandrogenism (ENDO 2025) - "Anastrozole was suspected to be the cause of her hyperandrogenism, so it was replaced with Tamoxifen. Sudden hyperandrogenism in postmenopausal women warrants investigation for hormonally active ovarian tumors. These tumors, though distressing, are curable with surgery. Long-term follow-up is essential to monitor for recurrence or metastasis, even in benign cases."

Acromegaly • Alopecia • Breast Cancer • Endocrine Disorders • Gynecology • Oncology • Ovarian Cancer • Polycystic Ovary Syndrome • Solid Tumor

Ovarian Stromal Hyperplasia: A Rare Cause of Hyperandrogenism in a 59-Year-Old Female With Treatment Related Menopause and Normal Imaging Findings (ENDO 2025) - "Her treatment for TNBC involved neoadjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel, anastrozole, and Xeloda which resulted in treatment related menopause...Because of the normal imaging findings, a 3-day dexamethasone suppression test was completed, which resulted in persistently elevated Testosterone levels... We present a rare case of hyperandrogenism that was found to be secondary to OSH and resulted in biochemical resolution after surgical intervention. The diagnosis of OSH is difficult but important to consider when the clinical suspicion is high."

Stroma • Alopecia • Breast Cancer • Gynecology • Oncology • Rare Diseases • Solid Tumor • Triple Negative Breast Cancer

Base-Promoted Iridium-Catalyzed Deuteration and C-H Bond Activation of N-Heterocycles. (PubMed, J Org Chem) - "In this work, we show that pharmaceuticals such as anastrozole, trimethoprim, and bisacodyl can be easily deuterated in up to 84-95%, with high site selectivity using an [IrCl(COD)(IMes)]/H2/NaOMe/methanol-d4 derived catalytic system. Four analogous C-H-bond-activated X-ray structures were obtained for the additional substrates. Catalytic turnover was found to dramatically increase upon the addition of NaOMe and is linked to a demonstrated role for trihydride species [Ir(H)3(COD)(IMes)] in the HIE process, with the reactive fragment {IrH(IMes)} implicated in the formation of catalytically competent dinuclear C-H bond activation products."

Journal

The gift that keeps on giving: Post-menopausal elevation in lipoprotein(a) (NLA 2025) - "The patient's cardiovascular risk was addressed with the addition of aspirin to her existing regimen of high-intensity statin and ezetimibe therapy...This effect was thought to be driven by tamoxifen withdrawal rather than directly from anastrozole itself. Further investigation is needed to elucidate the mechanism of Lp(a) expression and its association with menopause and aromatase inhibitors. This will help inform whether repeat Lp(a) testing is warranted in post-menopausal women to guide CV risk-management in this elevated risk population."

Atherosclerosis • Breast Cancer • Dyslipidemia • Genetic Disorders • Gynecology • Hormone Receptor Breast Cancer • Metabolic Disorders • Obesity • Oncology • Solid Tumor • ER

Cardiovascular risks associated with aromatase inhibitors versus tamoxifen in breast cancer: A systematic review and meta-analysis. (ASCO 2025) - "Funded by No funding sources reported Background: Aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane, are commonly used in the treatment of women with early or advanced-stage breast cancer (BC). This systematic review and meta-analysis indicate that AI treatment in BC patients is associated with an increased risk of heart failure, cardiomyopathy, and myocardial infarction. Notably, AI treatment demonstrated a protective effect against thromboembolic events."

Retrospective data • Review • Breast Cancer • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Ischemic stroke • Myocardial Infarction • Oncology • Solid Tumor

ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study. (ASCO 2025) - P2 | "Eligible pts will be randomized 1:1:1 to alisertib 30 mg, 40 mg, or 50 mg orally twice daily on days 1−3, 8–10, and 15–17 every 28 days, plus physician's choice of anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen not previously used in recurrent/metastatic setting or progressed upon in adjuvant setting; ≤50 pts will be enrolled per arm in the USA and Europe. Tumor tissue will be centrally assessed for biomarkers, including RB1, MYC, TP53, ESR1, PI3K/AKT pathway, HER2 and AURKA genomic alterations/expression levels. The study will determine the optimal alisertib dose to combine with ET and may identify biomarker(s) defining pts with the greatest benefit from alisertib-based therapy."

Clinical • Combination therapy • Metastases • P2 data • Anemia • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Leukopenia • Neutropenia • Oncology • Solid Tumor • ER • HER-2 • MYC • RB1

First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice. (ASCO 2025) - P2 | " Pre- and perimenopausal women (N = 222) with no prior systemic therapy for clinically aggressive HR+/HER2− ABC were randomized 1:1 to receive RIB + letrozole or anastrozole + goserelin or physician's choice of combo CT. This analysis from RIGHT Choice showed similar clinically meaningful efficacy and quality-of-life benefits and no new safety signals for RIB + ET vs combo CT between pts with and without liver mets. These results support the 1L use of RIB + ET in pts with clinically aggressive HR+/HER2– ABC even in the presence of liver mets. NE, not evaluable."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors. (ASCO 2025) - P2, P3 | " OPERA-01 (NCT06016738) is a multicenter, randomized, open-label, phase 3 clinical trial comparing the efficacy and safety of palazestrant as a single agent to SOC ET (fulvestrant, anastrozole, letrozole, or exemestane) in patients with ER+, HER2– MBC that relapsed or progressed on 1-2 prior lines of ET, including a CDK4/6i. Secondary endpoints include overall survival, antitumor activity (objective response rate, clinical benefit rate, and duration of response), safety, exposure and patient-reported outcomes in patients with and without ESR1 mutations. Study recruitment began in November 2023."

Clinical • Metastases • Monotherapy • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

A process evaluation trial of a telehealth service intervention to support uptake of breast cancer prevention medications. (ASCO 2025) - "Funded by Tour de Cure , National Health and Medical Research Council (Australia) Clinical Trial Registration Number: 15718519 Background: Breast cancer prevention medications (BCPrevMeds), such as tamoxifen and anastrozole, halve breast cancer (BC) risk. Currently 33 of a planned 63 participants have been recruited - sample size is based on 80% power to detect a change in uptake from 2% to 20%. Clinical Trial Information: ISRCTN 15718519"

Breast Cancer • Oncology • Solid Tumor

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. (ASCO 2025) - P3 | " Pts with HR+/HER2– ABC who had received ≥6 months of 1L AI (anastrozole/letrozole) + CDK4/6i (abemaciclib/palbociclib/ribociclib) were enrolled and had ctDNA tested for ESR1m every 2–3 months, coinciding with routine imaging. Camizestrant + CDK4/6i guided by emergence of ESR1m during 1L AI + CDK4/6i in pts with HR+/HER2– ABC resulted in a statistically significant and clinically meaningful improvement in PFS. SERENA-6 is the first global Phase 3 trial to demonstrate clinical utility of using ctDNA to detect and treat emerging resistance, ahead of disease progression. These findings represent a potential new treatment strategy to optimize and improve 1L patient outcomes."

Circulating tumor DNA • Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC). (ASCO 2025) - P3 | "Pts will receive RIB (400 mg/d; 3 wk on/1 wk off) + ET (letrozole 2.5 mg/d, anastrozole 1 mg/d, or exemestane 25 mg/d) for 36 months, followed by ET alone as SOC per investigator's clinical judgment. Pre/peri-menopausal women and men will receive goserelin 3.6 mg or leuprolide 3.75 mg/4 wk...Recruitment is ongoing. Clinical trial information: NCT05827081."

Clinical • P3 data • Breast Cancer • Heart Failure • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2

Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial. (ASCO 2025) - P3 | "Patients (pts) were randomized (1:1) to receive oral Dalp (125 mg QD; 3-wk on/1-wk off, for 2 y) + ET (letrozole 2.5 mg/anastrozole 1 mg/tamoxifen 10 mg/toremifene 60 mg QD, for 5 y) or placebo + ET. Addition of Dalp to ET as adjuvant treatment significantly improved iDFS, with a tolerable safety profile. These data support the use of Dalp for treating HR+/HER2- early BC. Efficacy outcomes.*Kaplan–Meier method."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (clinicaltrials.gov) - P3 | N=698 | Completed | Sponsor: Institute of Cancer Research, United Kingdom | Unknown status ➔ Completed

Trial completion • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • PGR

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov) - P3 | N=315 | Active, not recruiting | Sponsor: AstraZeneca | Trial primary completion date: Apr 2025 ➔ Jul 2025

Circulating tumor DNA • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

STX-478-101: First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=720 | Recruiting | Sponsor: Scorpion Therapeutics, Inc. | N=400 ➔ 720

Enrollment change • Monotherapy • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PIK3CA

Pharmaceutical And Lifestyle Solutions For Male Infertility (ACSM 2025) - "Ordered blood work and sperm analysis. FINAL DIAGNOSIS: He was prescribed enclomiphene and anastrozole (1 mg twice/week), without altering his thyroid medication (Synthroid 100 mcg/d). He also underwent a comprehensive lifestyle modification program, incorporating a plant-based Mediterranean diet, increased physical activity, and targeted supplementation."

Fatigue • Gynecology • Infertility • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Sexual Disorders • Urology

Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? (PubMed, Cardiooncology) - "AI use is associated with a higher risk of AF than tamoxifen in the first 5 years of treatment, but the risk equalizes at 10 years. Long-term hormonal therapy has an increased risk of AF, highlighting the need for ongoing monitoring and management of risk factors."

Journal • Atrial Fibrillation • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

Anastrozole-induced autoimmune hepatitis: a rare case report and literature review. (PubMed, Oxf Med Case Reports) - "Clinicians should be aware of drug-induced AIH as a rare but life-threatening complication of anastrozole and potentially other aromatase inhibitors."

Journal • Autoimmune Hepatitis • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hepatitis B • Hepatology • Hormone Receptor Breast Cancer • Immunology • Inflammation • Liver Failure • Oncology • Solid Tumor • ER

Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in elderly women with HR+/HER-2 metastatic or advanced breast cancer: patient-level network meta-analysis. (PubMed, Aging (Albany NY)) - "In this network meta-analysis, the combination of Palbociclib with Letrozole or Fulvestrant was found to have an effect on PFS and OS, and Ribociclib + Let was found to be a relatively safe treatment option for elderly women with HR+/HER2 metastatic or advanced BC. However, given the limited evidence in older populations, comprehensive, well-designed, large-scale randomized controlled trials are needed to address this issue."

Journal • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database. (PubMed, Front Pharmacol) - "Sixty-one preferred terms (PTs) presented positive signals, including nail disorders, onychoclasis, and abnormal hair growth in patients on anastrozole, exemestane, or letrozole. Eleven dermatologic PTs had onset times under 50 days, with the earliest at 2 days; the latest, skin ulcer, appeared at 241.5 days with exemestane. The findings provide substantial evidence of dermatologic AEs associated with AIs, particularly anastrozole and exemestane, emphasizing the importance of dermatologic monitoring during AI therapy and the need for further research into AI-induced dermatologic AEs."

Adverse events • Journal • Dermatology

OPERA-01: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=510 | Recruiting | Sponsor: Olema Pharmaceuticals, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Monotherapy • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

A Squeaky Lung Mass: A Case of a Rare NTM Disease (ATS 2025) - "We present the case of a 67-year-old female with a medical history of Hodgkin's disease treated with mantle radiation, breast cancer treated with bilateral mastectomy on anastrozole, and progressive lung disease with bronchiectasis status post-right middle and lower lobe lobectomies...Albuterol, N-acetylcysteine, as well as multiple courses of suppressive antibiotics with azithromycin and trimethoprim-sulfamethoxazole over several years provided some relief...The patient started on moxifloxacin, rifabutin, and ethambutol...Due to her history of bronchiectasis and lung resection, parenteral amikacin was considered. Once diagnosed, treatment courses are recommended to continue for at least 12 months from culture conversion. If culture conversion is not achieved, surgical intervention may be a consideration if tolerated, with an 87% culture conversion rate."

Clinical • Breast Cancer • Bronchiectasis • Hodgkin Lymphoma • Infectious Disease • Nontuberculous Mycobacterial Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor